Bulgaria's Sopharma Trading 9-mo cons net profit edges up

The company's operating revenue leapt to 1.23 billion levs in January-September from some 1.1 billion levs a year earlier, Sopharma Trading said in an interim financial statement on Wednesday.

Sales to hospitals added 21.6% on the year to 301.9 million levs, while sales through pharmacies climbed by 9.1% to 745.2 million levs. At the same time, wholesale volume went up 14.4% year-on-year to 164.6 million levs, whereas sales of medical devices declined by 3.4% to 13.1 million levs.

Sopharma Trading's operating expenses rose by an annual 13% to 1.2 billion levs in the first nine months of this year, with the cost of goods sold expanding to 1.08 billion levs from 958.7 million levs in the like period of 2022.

The company's biggest shareholder is Bulgarian drug maker Sopharma [BUL:SFA], which held a stake of 87.45% at the end of September.

Shares in Sopharma Trading last traded on Wednesday when they closed at 5.85 levs on the Bulgarian Stock Exchange, bourse data show.

(1 euro = 1.95583 levs)